SHANGHAI, Feb. 4, 2023
/PRNewswire/ -- Qiming Venture Partners' portfolio company
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical stage global
biopharmaceutical company focusing on novel oral small molecule
therapeutics, successfully debuts on Nasdaq on February 3
Beijing Time. It issued at $15.00 per ADS, opened at
$25.00 per ADS and up by 66.67%,
representing a market cap of $915
million.
As an early investor, Qiming first invested in the company's
series A round in 2019 and continued to participate in its A+ and B
rounds. This successful IPO also marks Qiming's second IPO in
2023.
Co-founded by Raymond Stevens,
Ph.D., a world-renowned pioneer in the field of structure-based
drug discovery, and another Qiming's portfolio company Schrödinger,
a leading player in computational physics-based drug design,
Structure Therapeutics' platform enables conversion of biologics
and peptide therapeutics into orally available small molecule drugs
with enhanced pharmaceutical properties, including improved
bioavailability and stability by leveraging structure-based drug
discovery and computational chemistry expertise.
Targeting G-protein-coupled receptors, or GPCRs, Structure
Therapeutics currently has a wholly owned pipeline of candidates,
including GSBR-1290 targeting GLP-1R, for the treatment of type-2
diabetes mellitus, or T2DM, and obesity, with Phase 1 single
ascending dose, or SAD study completed in September 2022, and next generation GLP-1R
candidates designed with customized properties to achieve
additional benefit. In September
2022, the company completed a Phase 1 SAD and MAD study
evaluating ANPA-0073 targeting the apelin receptor, or APJR, for
the treatment of patients with diopathic pulmonary fibrosis, or
IPF, and pulmonary arterial hypertension, or PAH. It is also
advancing a differentiated lysophosphatidic acid 1 receptor, or
LPA1R, antagonist for the treatment of IPF.
"We are pleased to have been one of the earliest investors and
accompanied Structure Therapeutics all the way to the IPO today, a
new milestone for the company", said Nisa
Leung, Managing Partner of Qiming Venture Partners, "Ever
since its inception, Structure Therapeutics has adopted an
innovative approach to address current challenges and built a
platform to find the best drug candidates. With a global team of
experts and their decades of experience, we look forward to
Structure Therapeutics further advancing product R&D,
commercialization, and corporate development to produce better and
more affordable medicines, addressing global unmet needs."
About Qiming Venture Partners
Founded in 2006, Qiming
Venture Partners is a leading China venture capital firm with offices in
Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San
Francisco Bay Area.
Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4
billion in capital raised. Since our establishment, we have
invested in outstanding companies in the Technology and Consumer
(T&C) and Healthcare industries at the early and growth
stages.
Since our debut, we have backed over 480 fast-growing and
innovative companies. Over 180 of our portfolio companies have
achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai
Stock Exchange or Shenzhen Stock Exchange, or through M&A or by
other means. There are also over 70 portfolio companies that have
achieved unicorn status.
Many of our portfolio companies are today's most influential
firms in their respective sectors, including Xiaomi (SEHK:1810),
Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu
(NYSE: ZH, SEHK: 2390), Roborock (SHSE:688169), Gan & Lee
Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347),
Zai Lab (NASDAQ:ZLAB, SEHK:9688),
CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger
(NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health
(SEHK:6606), Venus MedTech (SEHK:2500), Sanyou Medical
(SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710),
SinocellTech (SHSE: 688520), Yuanxin Technology, Caidya, Belief
BioMed, WeRide, Biren Technology and UBTech among many others.
View original
content:https://www.prnewswire.com/news-releases/qiming-venture-partners-backed-structure-therapeutics-successfully-debuts-on-nasdaq-301738824.html
SOURCE Qiming Venture Partners